Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)

Article ID	Journal	Published Year	Pages	File Type
8679308	Thrombosis Research	2018	6 Pages	PDF

Abstract

Novel therapeutic option for thrombotic diseases: DS-1040 is a potent, selective, intravenously/orally available inhibitor of TAFIa with minimum risk of bleeding. DS-1040 is a potential novel fibrinolysis enhancer useful in treating thrombotic diseases.193

Keywords

APTT t-PA PrP TAFIa PCI CPN rt-PA Oral administration Thrombolytic therapy activated partial thromboplastin time prothrombin time Tissue factor Fibrinolytic agents Tissue-plasminogen activator thrombin-activatable fibrinolysis inhibitor platelet-rich plasma carboxypeptidase N

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Preview

Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)

Authors

Kengo Noguchi, Naoko Edo, Naoki Miyoshi, Aya Isobe, Akiko Watanabe, Yusuke Ito, Yoshiyuki Morishima, Kyoji Yamaguchi,